Webinar description

Canada’s new Controlled Substances Regulations mark an important shift in how controlled substances are regulated nationally. But what do these changes actually mean for patients, practitioners, pharmacists, clinics, and the future of psychedelic-assisted therapy? Join our panel as we unpack what changes are in place for psilocybin and MDMA (and other psychedelics!) authorization through the Special Access Program, and what remains unchanged. We’ll also explore the general practical implications for SAP prescribing, possession, storage, transportation, administration, drug accountability, and professional scope. and what the new framework and private member bills could mean for future psychedelic access in Canada.

    1. What Canada’s New Controlled Substances Regulations Mean for Psychedelics

About this webinar

  • $10.00
  • 1 hour of video content

Panelists

  • Dr. Houman Farzin

  • Jagpaul Kaur Deol

  • Harrison Jordan

Hosts

  • Rielle Capler

Learning Objectives

  • Describe the key changes introduced by Canada’s new Controlled Substances Regulations effective October 1, 2026.

  • Identify practical implications for healthcare professionals, including possession, storage, transportation, administration, and drug accountability.

  • Recognize what the regulatory changes do (and do not) mean for psychedelic access, professional scope of practice, and patient care in Canada.

  • Discuss proposed Private Members’ Bills and other legislative proposals and their potential implications for psychedelic access in Canada.

Start your learning journey

Enroll today

Categories